Lakeside Advisors INC. Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Lakeside Advisors INC. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 11.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,818 shares of the biopharmaceutical company’s stock after buying an additional 1,003 shares during the quarter. Lakeside Advisors INC.’s holdings in Pfizer were worth $284,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in PFE. China Universal Asset Management Co. Ltd. purchased a new stake in Pfizer during the first quarter worth about $315,000. Norden Group LLC raised its stake in shares of Pfizer by 26.8% in the first quarter. Norden Group LLC now owns 30,336 shares of the biopharmaceutical company’s stock valued at $842,000 after acquiring an additional 6,404 shares in the last quarter. Connecticut Wealth Management LLC boosted its holdings in Pfizer by 11.8% in the first quarter. Connecticut Wealth Management LLC now owns 18,279 shares of the biopharmaceutical company’s stock valued at $507,000 after purchasing an additional 1,936 shares during the period. Sippican Capital Advisors increased its holdings in Pfizer by 21.5% during the 1st quarter. Sippican Capital Advisors now owns 82,762 shares of the biopharmaceutical company’s stock worth $2,297,000 after purchasing an additional 14,618 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 6.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 137,125 shares of the biopharmaceutical company’s stock valued at $3,805,000 after buying an additional 7,718 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on PFE shares. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $28.08 on Friday. The business has a 50 day moving average price of $29.03 and a 200 day moving average price of $28.57. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market capitalization of $159.12 billion, a P/E ratio of 37.95, a PEG ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.98%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.